Related Experiment Video

Updated: Dec 23, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

20.1K

Role of thrombospondin‑1 and thrombospondin‑2 in cardiovascular diseases (Review)

Kaijie Zhang1, Miaomiao Li1, Li Yin1

  • 1Department of Vascular Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China.

International Journal of Molecular Medicine
|April 24, 2020
PubMed

Insights

Thrombospondin (TSP)-1 and TSP-2 are key extracellular matrix proteins involved in cardiovascular diseases (CVDs). Understanding their interactions and pathways offers new therapeutic strategies for CVD treatment.

Area of Science:

  • Cardiovascular Biology
  • Extracellular Matrix Research
  • Molecular Medicine

Background:

  • Thrombospondin (TSP)-1 and TSP-2 are matricellular proteins found in the extracellular matrix (ECM).
  • These proteins play a significant role in the pathological processes of various cardiovascular diseases (CVDs).
  • Their diverse functions stem from interactions with numerous ligands, including ECM components, cytokines, and growth factors.

Purpose of the Study:

  • To summarize the current understanding of TSP-1 and TSP-2 roles in various CVDs.
  • To discuss the interacting ligands and signaling pathways associated with TSP-1 and TSP-2 in the context of CVDs.
  • To explore the potential of targeting TSP-1 and TSP-2 for novel CVD therapies.

Main Methods:

  • Literature review synthesizing existing research on TSP-1 and TSP-2 in cardiovascular pathology.
  • Analysis of molecular interactions between TSP-1/TSP-2 and their ligands.
  • Discussion of cellular mechanisms regulated by TSP-1/TSP-2 in CVDs.

Main Results:

  • TSP-1 and TSP-2 regulate ECM remodeling, cell migration, dysfunction, and apoptosis in CVDs.
  • These proteins modulate various cellular activities through interactions with a wide array of molecular partners.
  • Specific signaling pathways influenced by TSP-1 and TSP-2 in different cardiovascular conditions have been identified.

Conclusions:

  • TSP-1 and TSP-2 are critical regulators in the pathogenesis of cardiovascular diseases.
  • Investigating their ligand interactions and signaling pathways provides insights into disease mechanisms.
  • Targeting TSP-1 and TSP-2 presents a promising avenue for developing new therapeutic strategies for CVDs.

More Related Videos

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.9K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
196
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
961
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
291
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
216